國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Access to non-summary clinical trial...

Kim, Daria.

Access to non-summary clinical trial data for research purposes under EU Law

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Access to non-summary clinical trial data for research purposes under EU Lawby Daria Kim.
作者:	Kim, Daria.
出版者:	Cham :Springer International Publishing :2021.
面頁冊數:	xviii, 300 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Clinical trialsLaw and legislationEuropean Union countries.
電子資源:	https://doi.org/10.1007/978-3-030-86778-2
ISBN:	9783030867782$q(electronic bk.)

Access to non-summary clinical trial data for research purposes under EU Law
Kim, Daria.

Access to non-summary clinical trial data for research purposes under EU Law[electronic resource] /by Daria Kim. - Cham :Springer International Publishing :2021. - xviii, 300 p. :ill., digital ;24 cm. - Munich studies on innovation and competition,v. 162199-7470 ;. - Munich studies on innovation and competition ;v.1..

PART ONE: Setting the Scene -- Introduction -- The Context and the Problem in Focus -- Secondary Analysis of Clinical Trial Data - A Primer -- PART TWO: Analysis de lege lata,- Legal Sources of Control over and Access to Clinical Trial Data under the EU Applicable Framework -- Implications of IPD Disclosure for Statutory Innovation Incentives PART THREE: Analysis de lege ferenda -- Defining the Intervention Logic of Access-To-Data Measures - A Problem Analysis -- Access to Clinical Trial Data as a Case on R&D Externalities - A Theoretical Framework -- IPD as a Research Resource - Exclusively Controlled or Readily Accessible? -- Evaluating Legislative Options -- Final Conclusions and the Outlook.

This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.

ISBN: 9783030867782$q(electronic bk.)

Standard No.: 10.1007/978-3-030-86778-2doiSubjects--Topical Terms:

908838
Clinical trials
--Law and legislation--European Union countries.

LC Class. No.: KJE6227 / .K55 2021

Dewey Class. No.: 344.4041

Access to non-summary clinical trial data for research purposes under EU Law
LDR:03304nmm a2200337 a 4500 001 610692
003 DE-He213
005 20211019132831.0
006 m d
007 cr nn 008maaau
008 220330s2021 sz s 0 eng d
020 $a 9783030867782$q(electronic bk.)
020 $a 9783030867775$q(paper)
024 7 $a 10.1007/978-3-030-86778-2 $2 doi
035 $a 978-3-030-86778-2
040 $a GP $c GP
041 0 $a eng
050 4 $a KJE6227 $b .K55 2021
072 7 $a LNJ $2 bicssc
072 7 $a LAW000000 $2 bisacsh
072 7 $a LNJ $2 thema
082 0 4 $a 344.4041 $2 23
090 $a KJE6227 $b .K49 2021
100 1 $a Kim, Daria. $3 908837
245 1 0 $a Access to non-summary clinical trial data for research purposes under EU Law $h [electronic resource] / $c by Daria Kim.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xviii, 300 p. : $b ill., digital ; $c 24 cm.
490 1 $a Munich studies on innovation and competition, $x 2199-7470 ; $v v. 16
505 0 $a PART ONE: Setting the Scene -- Introduction -- The Context and the Problem in Focus -- Secondary Analysis of Clinical Trial Data - A Primer -- PART TWO: Analysis de lege lata,- Legal Sources of Control over and Access to Clinical Trial Data under the EU Applicable Framework -- Implications of IPD Disclosure for Statutory Innovation Incentives PART THREE: Analysis de lege ferenda -- Defining the Intervention Logic of Access-To-Data Measures - A Problem Analysis -- Access to Clinical Trial Data as a Case on R&D Externalities - A Theoretical Framework -- IPD as a Research Resource - Exclusively Controlled or Readily Accessible? -- Evaluating Legislative Options -- Final Conclusions and the Outlook.
520 $a This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results. Pro-access policy initiatives have been strongly opposed by research-based drug companies arguing that mandatory data disclosure impedes their innovation incentives. Conventionally, access to test data has been approached from the perspective of transparency and research ethics. The book offers a complementary view and considers access to individual patient-level trial data for exploratory analysis as a matter of research and innovation policy. Such approach appears to be especially relevant in the data-driven economy where digital data constitutes a valuable economic resource. The study seeks to define how the rules of access to clinical trial data should be designed to reconcile the policy objectives of leveraging the research potential of data through secondary analysis, on the one hand, and protecting economic incentives of research-based drug companies, on the other hand. Overall, it is argued that the mainstream innovation-based justification for exclusive control over the outcomes of research and development can hardly rationalise trial sponsors' control over primary data from trials. Instead, access to such data and its robust analysis should be prioritised.
650 0 $a Clinical trials $x Law and legislation $z European Union countries. $3 908838
650 0 $a Freedom of information $z European Union countries. $3 831542
650 1 4 $a IT Law, Media Law, Intellectual Property. $3 823867
650 2 4 $a Medical Law. $3 275623
650 2 4 $a European Law. $3 558717
650 2 4 $a Biomedicine, general. $3 853300
650 2 4 $a Statistics, general. $3 275684
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Munich studies on innovation and competition ; $v v.1. $3 711384
856 4 0 $u https://doi.org/10.1007/978-3-030-86778-2
950 $a Law and Criminology (SpringerNature-41177)